Coeptis Therapeutics Warrants
COEPW
COEPW was delisted on the 24th of April, 2026.
9 hedge funds and large institutions have $1.95M invested in Coeptis Therapeutics Warrants in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
+$364K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$348K |
| 3 |
ICM
Ionic Capital Management
New York
|
+$305K |
| 4 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$163K |
| 5 |
Walleye Capital
New York
|
+$69.4K |
Top Sellers
COEPW Hedge Fund Activity: Q4 2020 in Review
9 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q4 2020, worth a combined $1.95M.
Buyers outnumbered sellers: 9 funds opened new COEPW positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $364K.
- 9 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.95M of Coeptis Therapeutics Warrants stock for Q4 2020.
- 9 funds opened new Coeptis Therapeutics Warrants positions in Q4 2020 and 0 closed out, a net change of +9 holders.
- The largest Coeptis Therapeutics Warrants buyer in Q4 2020 was Owl Creek Asset Management, an estimated $364K added.
Based on aggregated 13F filings for Q4 2020.